The expression of RANKL and OPG in the various grades of osteoarthritic cartilage.
The objective of the study was to determine whether cartilage expression of the bone regulating molecules receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) varies between the different grades of osteoarthritis (OA). Cartilage samples were obtained from 30 patients undergoing total hip/knee replacement surgery. Tissue sections were stained with Safranin O and graded. Immunohistochemical staining was then performed, and levels of RANKL and OPG expression were assessed using a semi-quantitative scoring system. In addition, levels of mRNA encoding for RANKL and OPG were determined by a relative real-time reverse transcription-polymerase chain reaction technique. We found that expression of RANKL protein, mRNA expression, and the ratio of RANKL: OPG mRNA was greater in grade 2 cartilage in comparison with grade 0 cartilage (P < 0.05). Increased RANKL staining in the grade 2 cartilage was predominantly in the peri-cellular region of the middle and deep zones as well as in the matrix of the superficial zone. OPG mRNA expression was greater in grade 3 cartilage in comparison with grade 0 cartilage (P < 0.05). Cartilage and subchondral bone are in close proximity and soluble proteins produced in the cartilage are likely to move from one compartment to the other. Our finding of increased expression of RANKL in grade 2 OA cartilage might explain the increase in bone turnover reported in the subchondral bone of OA patients. The changes seen in the different grades of tissue may also indicate that this effect occurs during the early stages of OA development.
Discipline of Pathology, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, North Terrace, Level 3 Medical School North Building, Frome Road, Adelaide, SA 5005, Australia.
Angus R
AR
Upton
Christopher A
CA
Holding
Anak A S S K
AA
Dharmapatni
David R
DR
Haynes
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000378:metabolism; D002358:Cartilage, Articular / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D005786:Gene Expression Regulation / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D053244:Osteoprotegerin / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D053245:RANK Ligand / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis
D015415:Biomarkers; D053244:Osteoprotegerin; D053245:RANK Ligand; D012333:RNA, Messenger; C505688:TNFSF11 protein, human
Osteoarthritis Cartilage. 2003 Mar;11(3):217-27
12623293
J Bone Miner Metab. 2007;25(4):219-25
17593491
Endocrinology. 2009 Nov;150(11):4823-34
19819969
J Electron Microsc (Tokyo). 2003;52(6):515-25
14756239
Rheumatology (Oxford). 2009 Dec;48(12):1482-90
19762475
Methods. 2001 Dec;25(4):402-8
11846609
Arthritis Rheum. 2004 Apr;50(4):1193-206
15077302
Clin Exp Rheumatol. 2008 Mar-Apr;26(2):295-304
18565252
Nature. 1999 Jan 28;397(6717):315-23
9950424
J Biomed Mater Res A. 2008 Mar 1;84(3):691-701
17635018
Arthritis Rheum. 2001 Dec;44(12):2768-76
11762937
Osteoarthritis Cartilage. 2006 Jan;14(1):13-29
16242352
Osteoarthritis Cartilage. 2008 Jun;16(6):638-46
18362080
Arthritis Res Ther. 2007;9 Suppl 1:S1
17634140
Endocrinology. 2001 Dec;142(12):5050-5
11713196
J Electron Microsc (Tokyo). 2003;52(6):503-13
14756238
Arthritis Rheum. 2004 Feb;50(2):341-4
14872473
J Mol Med (Berl). 2001 Jun;79(5-6):243-53
11485016
Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii32-9
12379618
Arthritis Rheum. 2007 Oct;56(10):3358-65
17907189
Clin Biochem. 2008 Jun;41(9):746-9
18355453
J Dent Res. 2006 Jul;85(7):627-32
16798863
Rheumatology (Oxford). 2003 Jan;42(1):123-34
12509625